Aspirin, metformin, and statin use on the risk of gastric cancer: A nationwide population‐based cohort study in Korea with systematic review and meta‐analysis

Cancer Medicine

Jinseob Kim¹  Chan Hyuk Park²  Seung In Seo³  Woon Geon Shin³  Tae Jun Kim⁴  Seng Chan You⁵  Hyon Hee Kim⁶  Chang Seok Bang⁷  Jae Young Kim⁸  Kyung Joo Lee⁸ 

[1] Department of Epidemiology School of Public Health Seoul National University Seoul Korea;Department of Internal Medicine Hanyang University Guri Hospital Hanyang University College of Medicine Guri Korea;Department of Internal Medicine Kangdong Sacred Heart Hospital Hallym University College of Medicine Seoul Korea;Department of Internal Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea;Department of Preventive Medicine Yonsei University College of Medicine Seoul Korea;Department of Statistics and Information Science Dongduk Women's University Seoul Korea;Institute for Liver and Digestive Diseases Hallym University Chuncheon Korea;University Industry Foundation Hallym University Chuncheon Korea;

关键词: aspirin;    chemoprevention;    gastric cancer;    metformin;    statin;   

DOI  :  10.1002/cam4.4514

来源: DOAJ

【 摘 要 】

Abstract Background/Aims Although several chemopreventive drugs against gastric cancer have been proposed, their effects have not been fully evaluated. We examined the impacts of aspirin, metformin, and statin use on gastric cancer development in a population‐based cohort in Korea. Methods We analyzed the association between potential chemopreventive drugs—aspirin, metformin, and statin—and gastric cancer through the Observational Medical Outcomes Partnership Common Data Model‐based Korean nationwide cohort. Use of aspirin, metformin, and statin was defined by ≥365 days of prescriptions for each drug in the general population. To summarize the current evidence, we further performed a systematic review and meta‐analysis of the impact of aspirin, metformin, and statin on gastric cancer development. Results After propensity score matching, 31,839, 6764, and 10,251 subjects were observed for medians of 4.7, 4.2, and 4.2 years for aspirin, metformin, and statin analysis, respectively. Use of aspirin or statin was associated with lower risks of gastric cancer compared to their non‐use, respectively (hazard ratio [HR] [95% confidence interval [CI]]: aspirin, 0.72 [0.60–0.85], p < 0.01; statin, 0.67 [0.49–0.92], p = 0.01). However, no association was observed between metformin use and gastric cancer development (HR [95% CI]: 0.85 [0.59–1.23], p = 0.40). A subgroup of subjects with diabetes mellitus showed a lower risk of gastric cancer development with statin use. The meta‐analysis showed the highest effect size of gastric cancer development for statin, followed by aspirin and metformin. Conclusions Statin and aspirin use were associated with significantly reduced risks of gastric cancer development, while the use of metformin was not associated with the gastric cancer risk. The protective effect of statin against gastric cancer was also significant in patients with diabetes mellitus.

【 授权许可】

Unknown